Helus Pharma™ (NASDAQ: HELP) shares forged ahead Tuesday. The New York-based company, a clinical stage pharmaceutical concern committed to helping minds heal by developing novel serotonergic agonists announced a collaboration with TARA Mind, which works with Veterans Exploring Treatment Solutions to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program for Major Depressive Disorder, while expanding mental health awareness and access within the veteran community.
This partnership directly aligns with President Trump’s April 18, Executive Order, “Accelerating Medical Treatments for Serious Mental Illness,” which emphasizes expanding clinical research participation and advancing innovative treatment approaches for populations, including veterans, who face disproportionately high rates of depression, PTSD, and suicide.
“Veterans face significant mental health challenges, and expanding awareness and access to clinical research opportunities is an important step toward improving outcomes,” said Eric So, Interim Chief Executive Officer of Helus Pharma.
“TARA Mind and VETS bring deep experience working with veteran communities. These collaborations will support recruitment efforts for our FDA Breakthrough Therapy-designated HLP003 program while aligning with the broader priorities highlighted in the recent Executive Order to expand research participation and advance innovative treatments for serious mental illness.”
HELP shares edged ahead 2.5 cents to $5.42.
Related Stories
